831-38-9

Basic information

• Product Name: 2-(4-Fluorobenzoyl)hydrazinecarbothioaMide
• Synonyms: 2-(4-Fluorobenzoyl)hydrazinecarbothioaMide;[(4-fluorobenzoyl)amino]thiourea;[(4-fluorophenyl)carbonylamino]thiourea;[[(4-fluorophenyl)-oxomethyl]amino]thiourea;10T-0800;AIDS224173;AIDS-224173;Benzoic acid, 4-fluoro-, 2-(aminothioxomethyl)hydrazide
• CAS NO: 831-38-9
• Molecular Formula: C₈H₈FN₃OS
• Molecular Weight: 213.2320232
• Mol File: 831-38-9.mol
• Article Data: 20

Chemical Properties

• Melting Point: 150 °C
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• PKA: 9.83±0.70(Predicted)
• CAS DataBase Reference: 2-(4-Fluorobenzoyl)hydrazinecarbothioaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Fluorobenzoyl)hydrazinecarbothioaMide(831-38-9)
• EPA Substance Registry System: 2-(4-Fluorobenzoyl)hydrazinecarbothioaMide(831-38-9)

Safety Data

• Hazardous Substances Data: 831-38-9(Hazardous Substances Data)

Usage

Description

2-(4-Fluorobenzoyl)hydrazinecarbothioamide is a chemical compound with the molecular formula C8H7FN2OS. It is a thioamide derivative featuring a fluorobenzoyl group attached to a hydrazinecarbothioamide moiety, known for its unique chemical structure and reactivity.

Uses

Used in Pharmaceutical Industry:
2-(4-Fluorobenzoyl)hydrazinecarbothioamide is used as an intermediate in the synthesis of various pharmaceuticals for its potential role in creating new drug formulations.
Used in Agrochemical Industry:
2-(4-Fluorobenzoyl)hydrazinecarbothioaMide also serves as an intermediate in the synthesis of agrochemicals, contributing to the development of new pesticides or other agricultural products.
Used in Cancer Treatment Research:
2-(4-Fluorobenzoyl)hydrazinecarbothioamide is used as a potential therapeutic agent in cancer treatment due to its demonstrated cytotoxic and anti-proliferative activities against cancer cells.
Used in Material Science and Polymer Development:
Owing to its unique chemical structure and reactivity, 2-(4-Fluorobenzoyl)hydrazinecarbothioamide may be utilized in the development of new materials and polymers, expanding its applications in various industries.

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 79-19-6 thiosemicarbazide 
• 456-06-4 4-fluorobenzoyl hydrazide 
• 333-20-0 potassium thioacyanate 
• 2714-90-1 phenyl 4-fluorobenzoate 
• 456-22-4 4-Fluorobenzoic acid 
• 403-33-8 methyl 4-flurobenzoate 

Downstream Products

• 942-70-1 5-(4-fluorophenyl)-1,3,4-thiadiazol-2-amine 
• 7659-07-6 2-amino-5-(4-fluorophenyl)-1,3,4-oxadiazole 
• 114058-91-2 5-(4-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione 
• 114058-91-2 3-(4-Fluoro)phenyl-5-mercapto-1,2,4-triazole 
• 435341-13-2 5-p-bromobenzoylmethylmercapto-3-p-fluorophenyl-s-triazole 
• 177713-71-2 (6R,7R)-7-Amino-3-[5-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 771453-96-4 (6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-3-[5-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 116850-62-5 3-(4-Fluoro-phenyl)-5-methylsulfanyl-4H-[1,2,4]triazole 
• 852-39-1 4-amino-N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-benzenesulfonamide 
• 980-45-0 4-acetylamino-N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-benzenesulfonamide 
• 1059-01-4 N-{4-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-ylsulfamoyl]-phenyl}-succinamic acid 
• 863-97-8 N-{4-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-ylsulfamoyl]-phenyl}-phthalamic acid 
• 1363773-47-0 3-(4-benzylpiperazino)propyl [5-(4-fluorophenyl)-4H-1,2,4-triazol-3-yl]sulfide 

Relevant articles and documents

Synthesis and preliminary anticancer activity assessment of n-glycosides of 2-amino-1,3,4-thiadiazoles

The addition of 2-amino-1,3,4-thiadiazole derivatives with parallel iodination of differ-ently protected glycals has been achieved using a double molar excess of molecular iodine under mild conditions. The corresponding thiadiazole derivatives of N-glycosides were obtained in good yields and anomeric selectivity. The usage of iodine as a catalyst makes this method easy, inexpen-sive, and successfully useable in reactions with sugars. Thiadiazole derivatives were tested in a panel of three tumor cell lines, MCF-7, HCT116, and HeLa. These compounds initiated biological response in investigated tumor models in a different rate. The MCF-7 is resistant to the tested com-pounds, and the cytometry assay indicated low increase in cell numbers in the sub-G1 phase. The most sensitive are HCT-116 and HeLa cells. The thiadiazole derivatives have a pro-apoptotic effect on HCT-116 cells. In the case of the HeLa cells, an increase in the number of cells in the sub-G1-phase and the induction of apoptosis was observed.

Novel panaxadiol triazole derivatives induce apoptosis in HepG-2 cells through the mitochondrial pathway

In this study, we introduced 1, 2, 4-triazole groups into panaxadiol (PD) to obtain 18 panaxadiol triazole derivatives. Five cancer cells and one normal cell were evaluated for cytotoxicity by MTT assay. The results showed that most of the derivatives could inhibit cancer cell proliferation, and the anti-proliferative activity of compound A1 was the most significant. For HepG-2 cells, the IC50 value was 4.21 ± 0.54 μM, which was nearly 15 times higher than the activity of PD. Further studies showed that compound A1 could induce apoptosis in HepG-2 cells, and could enhance the expression of Cl-caspase-3, Cl-caspase-9 and Cl-PARP. Moreover, Western blot analysis showed that after treating HepG-2 cells with compound A1, the expression of p53 protein was increased and the ratio of Bax/Bcl-2 was gradually increased. The cytoplasmic Bax is then translocated to the mitochondria, causing the release of Cyt c protein. Therefore, the results indicate that compound A1 induces apoptosis through the mitochondrial pathway and can be used the potential to develop new anti-proliferative agents.

Design and synthesis of 2,6-di(substituted phenyl)thiazolo[3,2-b]-1,2,4-triazoles as α-glucosidase and α-amylase inhibitors, co-relative Pharmacokinetics and 3D QSAR and risk analysis

Ten fused heterocyclic derivatives bearing the 2,6-di(subsituted phenyl)thiazolo[3,2-b]-1,2,4-triazoles as central rings were synthesized and structures of the compounds were established by analytical and spectral data using FTIR, EI-MS, 1H NMR and 13C NMR techniques. In vitro inhibitory activities of synthesized compounds on α-amylase, α-glucosidase and α-burylcholinesterase (α-BuChE) were evaluated using a purified enzyme assays. Compound 5c demonstrated strong and selective α-amylase inhibitory activity (IC50?=?1.1?μmol/g). 5?g exhibited excellent inhibition against α-glucosidase (IC50?=?1.2?μmol/g) when compared with acarbose (IC50?=?4.7?μmol/g) as a positive reference. Compound 5i was found to be most potent derivative against α-BuChE with the IC50 of 1.5?μmol/g which was comparable to the value obtained for (4.7?μmol/g) positive control (i.e. galantamine hydrobromide). Molecular dockings of synthesized compounds into the binding sites of human pancreatic α-amylase, intestinal maltase-glucoamylase and neuronal α-butrylcholinesterase allowed to shed light on the affinity and binding mode of these novel inhibitors. Preliminary structure–activity relationship (SAR) studies were carried out to understand the relationship between molecular structural features and inhibition activities of synthesized derivatives. These data suggested that compounds 5c, 5?g and 5i are promising candidates for hitto- lead follow-up in the drug-discovery process for the treatment of Alzheimer's disease and hyperinsulinamia.